PAYRETAILERS
3.2.2023 09:01:36 CET | Business Wire | Press release
PayRetailers, LATAM’s leading all-in-one payment technology provider, has announced today the appointment of Lorenzo Pellegrino as Chief Operating & Digital Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230203005003/en/
Lorenzo Pellegrino, Chief Operating & Digital Officer (Photo: PayRetailers)
Pellegrino comes to PayRetailers at a time of rapid growth, as it has expanded from seven to 11 offices, more than doubled headcount to over 200, and acquired Paygol in Chile and Pago Digital in Colombia. He will lead the deployment of PayRetailers’ resources, working to enhance the company’s technology offering and international platform – to support the merchant community, and the way it can access and move funds quickly and safely.
Payment industry leader
Pellegrino is a highly respected payments industry leader with almost 20 years of senior management experience. Most recently he was CEO of Skrill and NETELLER, heading their digital wallets businesses, alongside leading the marketing affiliate services company, Income Access – all part of the Paysafe Group Plc. While there, he coordinated efforts to drive Paysafe’s 2021 IPO on the New York Stock Exchange (NYSE).
Between 2012 and 2015, Pellegrino was also Executive Vice President for Digital Development for Optimal Payments Plc, leading their go-to-market strategy of the NETELLER wallet business and acquisition of Skrill. He spearheaded the company’s effort in integrating both wallet businesses which led to significant operational efficiencies and margin optimization. Before joining Optimal Payments, he held various executive level positions at Skrill (previously known as Moneybookers) and led their business development efforts in the US.
Lorenzo Pellegrino, COO & CDO, commented: “I’m thrilled to have joined a fast-growing business with so much potential. PayRetailers has a great business model and talented management team that will capitalize on the evolving payments landscape. Innovation and collaboration among our teams will lead us to great achievements and I am impressed by the team’s ability to deliver quality new products at speed.
“There are tremendous opportunities ahead and together we will seek to deliver greater value for our customers as we scale the business. Having been CEO in my previous role, I have a deep appreciation of what it takes to bring a business like PayRetailers to the next level of growth. I look forward to working with the board and leadership team as we usher in PayRetailers’ next chapter of growth and success, and I thank them for their warm welcome.”
Juan Pablo Jutgla, CEO & Founder of PayRetailers, commented: “In Lorenzo, we have chosen a leader uniquely positioned to execute and evolve PayRetailers’ strategy while continuing to generate growth. He has earned a reputation as a strong business leader with immense sector knowledge and has an excellent track record of leading businesses in both developed and emerging markets.
“We believe his strong leadership experience will help focus PayRetailers to become the payment method of choice to increase our community of merchants. We are delighted he will be supporting the company into a bright future and are excited as we enter the next chapter in PayRetailers’ journey.”
For more information about PayRetailers, please visit the company's website at https://payretailers.com.
About PayRetailers
Founded in 2017, PayRetailers is a leading global provider of online payment services with Latin DNA. Through one direct API, one technology platform and one contract, PayRetailers offer global merchants more than 250 payment methods without the need of a local entity.
PayRetailers platform provides businesses the ability to manage their payment ecosystem, analyze data, and simplify their customer experience through fully integrated solutions.
PayRetailers is headquartered in Spain with regional offices in Argentina, Brazil, Chile, Colombia, Mexico, Costa Rica, Paraguay and Peru.
Website: https://www.payretailers.com
LinkedIn: https://www.linkedin.com/company/pay-retailers/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230203005003/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom